Why the study?
Does rosiglitazone increase plasma adiponectin levels in type 2 diabetic patients?
Population
64 Type 2 diabetic patients
Comparison
Rosiglitazone for 6 months vs Placebo
Design
RCT, randomized, double-blind
Follow-up
6 months
Authors
Loading...
Adiponectin rise may mediate rosiglitazone benefits in T2D; extends prior mechanistic hypotheses with RCT confirmation.
Does rosiglitazone increase plasma adiponectin levels in type 2 diabetic patients?
Rosiglitazone significantly increases plasma adiponectin levels in patients with type 2 diabetes, suggesting a potential mechanism for its metabolic and antiatherogenic benefits.
Yang et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: